Pregnant women face a clinical dilemma when prescribed aspirin to prevent preeclampsia: does the higher dosing needed for effectiveness increase dangerous bleeding during delivery? This question has intensified as research suggests standard 81mg doses may be insufficient, while European trials use 150mg daily. A new analysis of 882 Canadian births provides reassuring evidence that doubling the standard aspirin dose to 162mg daily does not significantly increase postpartum hemorrhage risk. The retrospective study compared women taking 162mg aspirin from 12-36 weeks of pregnancy against matched controls, finding hemorrhage rates of 12.1% versus 7.0% respectively—a difference that fell short of statistical significance despite the numerical gap. Cesarean delivery outcomes showed virtually identical bleeding rates between groups. These findings matter because preeclampsia affects roughly 5% of pregnancies and remains a leading cause of maternal mortality worldwide. The condition's prevention often requires aspirin doses higher than the 81mg typically available in North America, yet bleeding concerns have made clinicians hesitant to prescribe optimal doses. This study suggests such caution may be unwarranted, though the research carries important limitations. The retrospective design cannot establish causation, and the study population was relatively small for detecting rare but serious bleeding events. Additionally, the numerical trend toward increased hemorrhage, while not statistically significant, warrants attention in larger prospective trials. The results align with emerging evidence that aspirin's antiplatelet effects may be less clinically relevant during the hemostatic stress of delivery than previously feared.